|Day Low/High||50.14 / 50.25|
|52 Wk Low/High||31.47 / 50.30|
In turn, this will increase the company's profit margins.
After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.
Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
David Einhorn is going all-in on General Motors.
New test provides powerful tool to help meet malaria eradication goals
Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.
Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.
Abbott Laboratories appears poised to enjoy a fruitful year, though its litigation with former takeover target Alere could hold it back.
First molecular test to detect RSV infection in 13 minutes or less now widely available in a broad range of healthcare settings
Abbott Labs' shares fell nearly 1% in premarket trading after the company reported mixed earnings results.